Published in Pain and Central Nervous System Week, January 23rd, 2006
The U.S. phase III clinical trial of Miraxion in Huntington disease commenced dosing in September 2005.
The European clinical trial is being conducted in collaboration with Icon and Euro-HD, a non-profit group of physicians and other healthcare professionals dedicated to the research and care of Huntington disease patients.
Rick Stewart, CEO of Amarin, commented; "The commencement of the 240 patient European phase III clinical trial in Huntington's disease is a major milestone for Amarin. The U.S. trial of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pain and Central Nervous System Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.